Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells
- PMID: 17463171
- PMCID: PMC1924475
- DOI: 10.1182/blood-2006-12-060947
Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells
Abstract
Chronic lymphocytic leukemia (CLL) is commonly defined as a disease of failed apoptosis of B cells and remains an incurable disease. The mechanism of resistance to apoptosis in CLL is complex and influenced by numerous factors, including nuclear factor kappaB (NFkappaB)-mediated expression of antiapoptotic molecules. Recent evidence indicates that glycogen synthase kinase-3beta (GSK-3beta) positively regulates NFkappaB-mediated gene transcription and cell survival. Using malignant B cells collected from patients with CLL, we find that both GSK-3beta and NFkappaB accumulate in the nucleus of CLL B cells, and pharmacologic inhibition of GSK-3 results in decreased expression of two NFkappaB target genes Bcl-2 and XIAP and a subsequent increase in CLL B-cell apoptosis ex vivo. Furthermore, we observed that inhibition of GSK-3 leads to a decrease in NFkappaB-mediated gene transcription but does not affect the nuclear accumulation of NFkappaB in CLL B cells. Last, using chromatin immunoprecipitation, we show that GSK-3 inhibition abrogates NFkappaB binding to its target gene promoters (XIAP, Bcl-2), in part through epigenetic modification of histones. Our results establish that inhibition of GSK-3 abrogates NFkappaB binding to its target gene promoters through an epigenetic mechanism, enhances apoptosis in CLL B cells ex vivo and identifies GSK-3 as a potential therapeutic target in the treatment of CLL.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1924475/bin/zh80150705600001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1924475/bin/zh80150705600002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1924475/bin/zh80150705600003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1924475/bin/zh80150705600004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1924475/bin/zh80150705600005.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1924475/bin/zh80150705600006.gif)
Similar articles
-
Activation of the Wnt signaling pathway in chronic lymphocytic leukemia.Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3118-23. doi: 10.1073/pnas.0308648100. Epub 2004 Feb 18. Proc Natl Acad Sci U S A. 2004. PMID: 14973184 Free PMC article.
-
Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells.Cancer Res. 2005 Mar 15;65(6):2076-81. doi: 10.1158/0008-5472.CAN-04-3642. Cancer Res. 2005. PMID: 15781615
-
Glycogen synthase kinase-3β inhibition induces nuclear factor-κB-mediated apoptosis in pediatric acute lymphocyte leukemia cells.J Exp Clin Cancer Res. 2010 Nov 26;29(1):154. doi: 10.1186/1756-9966-29-154. J Exp Clin Cancer Res. 2010. PMID: 21110852 Free PMC article.
-
Epigenetic alterations in a murine model for chronic lymphocytic leukemia.Cell Cycle. 2009 Nov 15;8(22):3663-7. doi: 10.4161/cc.8.22.9957. Cell Cycle. 2009. PMID: 19901553 Free PMC article. Review.
-
Potential Relevance of B-cell Maturation Pathways in Defining the Cell(s) of Origin for Chronic Lymphocytic Leukemia.Hematol Oncol Clin North Am. 2021 Aug;35(4):665-685. doi: 10.1016/j.hoc.2021.03.002. Epub 2021 Jun 2. Hematol Oncol Clin North Am. 2021. PMID: 34174979 Review.
Cited by
-
Strategies that regulate LSD1 for novel therapeutics.Acta Pharm Sin B. 2024 Apr;14(4):1494-1507. doi: 10.1016/j.apsb.2024.01.005. Epub 2024 Jan 10. Acta Pharm Sin B. 2024. PMID: 38572094 Free PMC article. Review.
-
The Effect of Sargassum Angustifolium-derived AgNPs on Apoptosis-associated Genes in Acute Lymphoblastic Leukemia Cells.Asian Pac J Cancer Prev. 2023 Aug 1;24(8):2691-2696. doi: 10.31557/APJCP.2023.24.8.2691. Asian Pac J Cancer Prev. 2023. PMID: 37642055 Free PMC article.
-
Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition.Cell Commun Signal. 2023 Jun 14;21(1):131. doi: 10.1186/s12964-023-01147-8. Cell Commun Signal. 2023. PMID: 37316860 Free PMC article.
-
Transcriptional Regulation during Aberrant Activation of NF-κB Signalling in Cancer.Cells. 2023 Mar 2;12(5):788. doi: 10.3390/cells12050788. Cells. 2023. PMID: 36899924 Free PMC article. Review.
-
GSK3 inhibitor enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance.EJHaem. 2022 Dec 12;4(1):153-164. doi: 10.1002/jha2.600. eCollection 2023 Feb. EJHaem. 2022. PMID: 36819180 Free PMC article.
References
-
- Call TG, Noel P, Habermann TM, Beard CM, O'Fallon WM, Kurland LT. Incidence of leukemia in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1994;69:315–322. - PubMed
-
- Catovsky D, Fooks J, Richards S. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults. Br J Haematol. 1989;72:141–149. - PubMed
-
- Jewell AP. Role of apoptosis in the pathogenesis of B-cell chronic lymphocytic leukaemia. Br J Biomed Sci. 2002;59:235–238. - PubMed
-
- Ogasawara T, Yasuyama M, Kawauchi K. Constitutive activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in B-cell lymphoproliferative disorders. Int J Hematol. 2003;77:364–370. - PubMed
-
- Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol. 2000;164:2200–2206. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA09724/CA/NCI NIH HHS/United States
- R01 CA095241-01/CA/NCI NIH HHS/United States
- CA95241/CA/NCI NIH HHS/United States
- R01 CA095241-04/CA/NCI NIH HHS/United States
- R01 CA095241-05/CA/NCI NIH HHS/United States
- P50 CA102701/CA/NCI NIH HHS/United States
- P20 CA102701/CA/NCI NIH HHS/United States
- R01 CA095241-02S1/CA/NCI NIH HHS/United States
- R01 CA095241-03/CA/NCI NIH HHS/United States
- R01 CA095241-02/CA/NCI NIH HHS/United States
- CA102701/CA/NCI NIH HHS/United States
- R01 CA095241/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical